MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Highlights
– In the phase 3 MAGNITUDE trial, addition of niraparib to abiraterone acetate plus prednisone (AAP) improved radiographic progression‑free survival (previously reported) and produced clinically meaningful improvements in time to symptomatic progression and time to cytotoxic chemotherapy in patients with HRR‑altered metastatic castration‑resistant prostate cancer (mCRPC), particularly those with BRCA1/2 alterations.
– At a median follow‑up of 37.3 months, final overall survival (OS) analysis showed no statistically significant OS advantage for niraparib + AAP versus placebo + AAP in the prespecified HRR‑altered population (HR 0.931; 95% CI 0.720–1.203; p=0.585) or BRCA1/2 subgroup (HR 0.788; 95% CI 0.554–1.120; nominal p=0.183).
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.